Quick Answer
Altimmune, Inc. reported Revenue (ASC 606) of $4.41 million for fiscal year 2021.
Altimmune, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2021 | $4.41M | -46.1% |
| 2020 | $8.19M | +41.1% |
| 2019 | $5.80M | -43.8% |
| 2018 | $10.33M | -3.8% |
| 2017 | $10.74M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2022 | $2.0K | -98.7% | -75.0% |
| June 30, 2022 | $8.0K | -94.2% | -75.0% |
| March 31, 2022 | $32.0K | -96.2% | -79.7% |
| September 30, 2021 | $158.0K | -94.6% | +15.3% |
| June 30, 2021 | $137.0K | -81.0% | -83.7% |
| March 31, 2021 | $838.0K | -62.1% | -71.5% |
| September 30, 2020 | $2.94M | +356.2% | +307.1% |
| June 30, 2020 | $721.6K | -55.6% | -67.4% |
- Altimmune, Inc. showed a decrease of -46.1% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2017–2021 period, Altimmune, Inc.’s revenue (asc 606) has declined by 58.9% (from $10.74 million to $4.41 million).
- The most recent figure is from Altimmune, Inc.’s fiscal year 2021 report (Form 10-K), filed with the SEC on March 15, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: